ليتروزول تيڤع

País: Israel

Língua: árabe

Origem: Ministry of Health

Ingredientes ativos:

LETROZOLE 2.5 MG

Disponível em:

TEVA PHARMACEUTICAL INDUST.LTD

Código ATC:

L02BG04

Forma farmacêutica:

TABLETS

Via de administração:

PER OS

Fabricado por:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Grupo terapêutico:

LETROZOLE

Indicações terapêuticas:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Data de autorização:

2010-01-01